Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO Direct Highlights Miami Symposium 2019 /
Latest updates in HER2-positive metastatic breast cancer: The NALA and SOPHIA trials

12th - 13th Jul 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 26.07.19
Views: 2035

Dr Connie Guaqueta - Memorial Cancer Institute, Miami, USA

Dr Connie Guaqueta speaks to ecancer at the 2019 ASCO Direct Highlights Symposium in Miami about the results from the phase III NALA and SOPHIA trials.

She firstly focuses on the NALA trial, which concluded that neratinib plus capecitabine is a new treatment option for patients with HER2-positive metastatic breast cancer, in comparison to lapatinib plus capecitabine - which is the current standard of care.

Dr Guaqueta also moves on to talk about the SOPHIA trial, which examined the effect of margetuximab plus chemotherapy versus trastuzumab plus chemotherapy. This trial unveiled the activity of margetuximab in this setting, however further data is needed to determine the role of this anti-HER2 antibody, within the current therapeutic landscape.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation